Literature DB >> 29339316

Diagnosis and management of neuromyelitis optica spectrum disorders - An update.

Alice Bruscolini1, Marta Sacchetti2, Maurizio La Cava3, Magda Gharbiya4, Massimo Ralli5, Alessandro Lambiase6, Armando De Virgilio7, Antonio Greco8.   

Abstract

Neuromyelitis optica (NMO) and Neuromyelitis optica spectrum disorders (NMOSD) are a group of autoimmune conditions characterized by inflammatory involvement of the optic nerve, spinal cord and central nervous system. Novel evidence showed a key role of autoantibodies against aquaporin-4 immunoglobulin G (AQP4 IgG) in the pathogenesis of NMOSD and, recently, new classification and diagnostic criteria have been adopted to facilitate an earlier identification and improve the management of these conditions. Diagnosis of NMOSD is currently based on clinical, neuroimaging and laboratory features. Standard treatment is based on the use of steroids and immunosuppressive drugs and aims to control the severity of acute attacks and to prevent relapses of the disease. This review gives an update of latest knowledge of NMOSD and NMO, emphasizing the novel diagnostic criteria and both current and future therapeutic approaches.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aquaporin-4 immunoglobulin G; Diagnostic criteria; Management; Neuromyelitis optica; Neuromyelitis optica spectrum disorders

Mesh:

Year:  2018        PMID: 29339316     DOI: 10.1016/j.autrev.2018.01.001

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  23 in total

Review 1.  Clinical Characteristics of Anti-N-Methyl-d-Aspartate Receptor Encephalitis Overlapping with Demyelinating Diseases: A Review.

Authors:  Shujiang Zhang; Yuan Yang; Wenyu Liu; Zuoxiao Li; Jinmei Li; Dong Zhou
Journal:  Front Immunol       Date:  2022-06-28       Impact factor: 8.786

2.  Affinity-matured 'aquaporumab' anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders.

Authors:  Tianjiao Duan; Lukmanee Tradtrantip; Puay-Wah Phuan; Jeffrey L Bennett; Alan S Verkman
Journal:  Neuropharmacology       Date:  2019-10-22       Impact factor: 5.250

3.  Moyamoya disease presenting as thalamic infarction in a patient with neuromyelitis optica spectrum disorder.

Authors:  Yin-Xi Zhang; Yang Zheng; Meng-Ting Cai; Lei Wu; Bao-Rong Zhang
Journal:  CNS Neurosci Ther       Date:  2019-02-06       Impact factor: 5.243

4.  CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica.

Authors:  Lukmanee Tradtrantip; Tianjiao Duan; Michael R Yeaman; Alan S Verkman
Journal:  J Neuroinflammation       Date:  2019-03-09       Impact factor: 8.322

5.  Neuromyelitis optica spectrum disorders with vertigo as the initial symptom: A case report.

Authors:  Qin Guo; Dexiong Han; Jing Liu; Kelin He; Ruijie Ma
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

Review 6.  Pregnancy-Related Immune Changes and Demyelinating Diseases of the Central Nervous System.

Authors:  Ke Qiu; Qiang He; Xiqian Chen; Hui Liu; Shuwen Deng; Wei Lu
Journal:  Front Neurol       Date:  2019-10-09       Impact factor: 4.003

7.  Free thyroxine level is associated with both relapse rate and poor neurofunction in first-attack Neuromyelitis Optica Spectrum Disorder (NMOSD) patients.

Authors:  Qianyi He; Lifeng Li; Yanfei Li; Yanhui Lu; Kaimin Wu; Ruiyi Zhang; Junfang Teng; Jie Zhao; Yanjie Jia
Journal:  BMC Neurol       Date:  2019-12-18       Impact factor: 2.474

8.  Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica.

Authors:  Tianjiao Duan; Alex J Smith; Alan S Verkman
Journal:  J Neuroinflammation       Date:  2018-10-22       Impact factor: 8.322

9.  Clinical Characteristics, Treatment Outcomes and Predictive Factors in Optic Neuritis.

Authors:  Linda Hansapinyo; Chayanee Vivattanaseth
Journal:  Open Ophthalmol J       Date:  2018-08-31

10.  Blood pressure and body fat percent in women with NMOSD.

Authors:  Xiaohong Chen; Rong Fan; Fuhua Peng; Jia Liu; Jing Huang; Zhigang Chen; Yong Chen; Ying Jiang
Journal:  Brain Behav       Date:  2019-08-03       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.